Novo Nordisk's Ozempic shortage expected to continue into Q4

Novo Nordisk (NOVOb.CO) said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.